SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Astex Pharmaceuticals
Information provided by (Responsible Party):
Astex Pharmaceuticals Identifier:
First received: November 29, 2010
Last updated: August 19, 2014
Last verified: August 2014

Phase 1-2 dose escalation randomized study in patients with intermediate or high risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). The Dose Escalation Segment will evaluate the biological activity, preliminary safety and efficacy of SGI-110 with two dosing schedules in MDS and AML patients while the Dose Expansion Segment will further evaluate safety and efficacy at the biological effective dose (BED) or maximum tolerated dose (MTD)as defined in the Dose Escalation Segment.

Condition Intervention Phase
Drug: SGI-110
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Resource links provided by NLM:

Further study details as provided by Astex Pharmaceuticals:

Primary Outcome Measures:
  • Dose Escalation Segment (Safety Lead-in): Determine the optimal BED or MTD and the frequency of drug administration. [ Time Frame: Assessed at the end of Course 1 (4 weeks) for each dose cohort. ] [ Designated as safety issue: Yes ]
    • Number of patients with adverse events.
    • Incidence of dose limiting toxicities.
    • Degree of hypomethylation as measured by LINE-1.

  • Dose Expansion Segment: Assess the activity of SGI-110 as measured by overall remission rate. [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
    Overall survival measured in weeks.

Secondary Outcome Measures:
  • Determine the pharmacokinetic profile of SGI-110 and decitabine. [ Time Frame: Assessed at the end of Course 1 (4 weeks) for each cohort. ] [ Designated as safety issue: No ]
    Cmax, Cmin, AUC and other secondary PK parameters of SGI-110 and decitabine in patients during Course 1.

  • Remission duration, hematological improvements and transfusion independence rates. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Assess remission duration, hematological improvement and transfusion independence rates as measured by weeks.

  • Determine epigenetic modulation in peripheral blood and bone marrow samples. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: December 2010
Estimated Study Completion Date: August 2015
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Daily Regimen
  • SGI-110 daily x5 dosing on a 28-day course
  • SGI-110 daily x10 dosing on a 28-day course
Drug: SGI-110
  • SGI-110 subcutaneous injection administered on Days 1-5
  • SGI-110 subcutaneous injection administered on Days 1-5 and 8-12
Experimental: Weekly Regimen
  • SGI-110 weekly dosing for three weeks on a 28-day course
  • SGI-110 twice weekly dosing for three weeks on a 28-day course
Drug: SGI-110
  • SGI-110 administered weekly on Days 1, 8 and 15
  • SGI-110 administered weekly on Days 1, 4, 8, 11, 15, and 18

Detailed Description:

Once the BED and MTD is determined in the Dose Escalation Segment, the Dose Expansion Segment will randomize patients with MDS, treatment naïve elderly AML, and relapsed/refractory AML patients to receive the BED or MTD dose. Relapsed/refractory AML patients may also receive SGI-110 on a daily x 10 schedule based on the total dose per cycle evaluated in the Dose Escalation Segment using the 5-daily regimen.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men or women, 18 years of age or older, with a confirmed diagnosis of international prognostic scoring system (IPSS) intermediate-1, intermediate-2 or high-risk MDS including Chronic Myelomonocytic Leukemia (CMML) or AML.

    • In the Dose Escalation Segment, patients who are refractory, relapsed, or unresponsive to standard treatment.
    • In the Dose Expansion Segment, hypomethylating agent (HMA) treatment-naïve MDS subjects (including CMML), and intermediate-2 or high-risk MDS subjects (including CMML) relapsed or refractory to prior HMA treatment are allowed, and treatment-naïve AML subjects who are at least 65 years of age will be allowed if they also have at least one of the following criteria

      • AML secondary to MDS, chemotherapy, or radiation therapy
      • poor cytogenetics
      • pre-existing clinically significant dysfunction of the heart or Chronic Obstructive Pulmonary Disease (COPD)
      • poor performance status, Eastern Cooperative Oncology Group (ECOG), of 2
  2. Eastern ECOG performance status of 0 to 2.
  3. Adequate organ function.
  4. Prior allogeneic stem cell transplant, no evidence of active graft-versus host disease (GVHD) and must be ≥ 2 weeks off immunosuppressive therapy.
  5. No major surgery within 4 weeks of first dose of SGI-110.
  6. No chemotherapy within 2 weeks of first dose of SGI-110 (minimum of 6 weeks for nitrosoureas and 8 weeks for bone marrow transplantation) with the exception of hydroxyurea which will be allowed during course 1 of treatment.
  7. Sign an approved informed consent form for this study.

Exclusion Criteria:

  1. In the Dose Expansion Segment, which includes the 10-day regimen, subjects who have received 2 complete full dose cycles or more of a hypomethylating agent (HMA) decitabine or azacitidine (except for intermediate-2 or high-risk MDS subjects (including CMML) relapsed or refractory to prior HMA treatment).
  2. Acute promyelocytic leukemia (M3 classification).
  3. Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the patient has been disease free for at least 3 years.
  4. Life-threatening illnesses other than AML or MDS, uncontrolled medical conditions or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, or put the study outcomes at risk.
  5. Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).
  6. Hypersensitivity to decitabine, SGI-110, or SGI-110 excipients.
  7. With the exception of treatment-naïve elderly AML patients, patients with uncontrolled congestive heart failure (CHF), coronary heart disease (CAD), chronic obstructive pulmonary disease (COPD), or left ventricular ejection fraction (LVEF) of ≤ 50% are excluded, symptomatic or uncontrolled arrhythmias or on continuous corticosteroids.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01261312

Contact: Sue Naim 925-560-0100

United States, Arizona
Mayo Clinic Recruiting
Scottsdale, Arizona, United States, 85259
Contact: Debbie Gallagher, RN         
Principal Investigator: Raoul Tibes, MD, PhD         
United States, California
University of Southern California Recruiting
Los Angeles, California, United States, 90033
Contact: Ibrahim Syed         
Principal Investigator: Casey O'Connell, MD         
United States, Connecticut
Yale University Recruiting
New Haven, Connecticut, United States, 06520
Contact: Stephanie Sellers         
Principal Investigator: Nikolai Podoltsev, M.D.         
United States, Florida
Florida Cancer Specialists - South Recruiting
Fort Myers, Florida, United States, 33916
Contact: Cara O'Keefe         
Principal Investigator: Thomas Ervin, M.D.         
Florida Cancer Specialists - North Recruiting
St. Petersburg, Florida, United States, 33705
Contact: Christina Beirmeier         
Principal Investigator: Joseph Mace, M.D.         
United States, Illinois
University of Chicago Cancer Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Michael Daunov         
Principal Investigator: Wendy Stock, MD         
United States, New York
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Theresa Hodin         
Principal Investigator: Elizabeth Griffiths, MD         
Cornell University Recruiting
New York, New York, United States, 10021
Contact: Evan O'Donnovan         
Principal Investigator: Gail Roboz, MD         
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Fiona Yeh         
Principal Investigator: Todd Rosenblat, M.D.         
United States, North Carolina
Duke University Recruiting
Durham, North Carolina, United States, 27705
Contact: Julie Warzecho         
Principal Investigator: David Rizzieri, MD         
United States, Ohio
Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Amiee Savillo         
Principal Investigator: Katherine Walsh, MD         
United States, Pennsylvania
Temple University Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Beth Giammaruti         
Principal Investigator: Patricia Kropf, MD         
United States, Tennessee
Tennessee Oncology Recruiting
Nashville, Tennessee, United States, 37203
Contact: Meredith Zimlich         
Principal Investigator: Michael Savona, MD         
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Contact: Meredith Zimlich         
Principal Investigator: Michael Savona, M.D.         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Cora Cheung         
Principal Investigator: Hagop Kantarjian, MD         
Canada, Ontario
Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Michelle Fantauzzi         
Principal Investigator: Karen Yee, MD         
Sponsors and Collaborators
Astex Pharmaceuticals
  More Information

No publications provided

Responsible Party: Astex Pharmaceuticals Identifier: NCT01261312     History of Changes
Other Study ID Numbers: SGI-110-01
Study First Received: November 29, 2010
Last Updated: August 19, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Astex Pharmaceuticals:
DNA Hypomethylating Agent
Intermediate 1, Intermediate 2, CMML or High Risk MDS

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms by Histologic Type processed this record on September 18, 2014